MYCN and retinoblastoma: For example, the rare and aggressive MYCN-amplified RB1-wildtype subtype retinoblastoma is more therapy resistant to traditional chemotherapies, but equally chemo-sensitive to pevonedistat (a neddylation inhibitor), which is being developed as treatment for neuroblastoma [28, 31–33].